Scientific Background BPC-157 was originally identified as part of a naturally occurring peptide sequence in gastric juice believed to contribute to the stomachs ability to resist injury
disease progression, surgical complications, or toxic effects of treatment that precluded the initiation of adjuvant therapy within 84 days after surgery
it is not extracted from meat and is fully suitable for vegans and vegetarians
It was first created to treat type 2 diabetes and has been shown to reduce blood sugar levels, reduce the risk of heart disease, and improve metabolic parameters
The study is the foundation for current anti-doping detection of IGF-1 analogs
In: Gopi S, Amalraj A, Kunnumakkara A, Thomas S (eds) Inflammation and natural products